Literature DB >> 2340210

Effect of predialysis verapamil on intradialytic blood pressure in chronic hemodialysis patients.

R A Sherman1, P Casale, R Cody, M W Horton.   

Abstract

Decreased left ventricular compliance because of hypertrophy or fibrosis may contribute to hypotension during hemodialysis. While calcium channel blockade may reduce intradialytic hypotension in patients with left ventricular hypertrophy and refractory pulmonary congestion, it is unknown whether such an effect might be seen in unselected hemodialysis patients. Verapamil (40 mg) or a placebo was given 1 hour before hemodialysis to 10 patients in a double-blind crossover study. Two 2 week verapamil periods alternated with two 2 week placebo periods. Patients received bicarbonate for either 3 hours (7 patients, high-flux, Filtral, Gambro-Hospal Inc., Williamsburg, VA) or for 4 hours (3 patients, Travenol 15.11 or CA 110, Baxter Healthcare, Deerfield, IL). Left ventricular hypertrophy was present by ultrasound in 7 of 8 patients tested and by electrocardiogram in 1 of the remaining 2. Intradialytic blood pressures were similar during the drug and placebo trials. The number of episodes of symptomatic hypotension per hemodialysis was 0.99 with verapamil and 0.93 during the placebo periods (p less than 0.05). Thus, a single predialysis dosage of verapamil has no effect on intradialytic blood pressure in an unselected hemodialysis population.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2340210     DOI: 10.1097/00002480-199004000-00005

Source DB:  PubMed          Journal:  ASAIO Trans        ISSN: 0889-7190


  4 in total

1.  Definitions of intradialytic hypotension.

Authors:  Magdalene M Assimon; Jennifer E Flythe
Journal:  Semin Dial       Date:  2017-07-09       Impact factor: 3.455

Review 2.  Impact of drugs on intradialytic hypotension: Antihypertensives and vasoconstrictors.

Authors:  Tara I Chang
Journal:  Semin Dial       Date:  2017-07-05       Impact factor: 3.455

3.  Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study).

Authors:  Christian Daugaard Peters; Krista Dybtved Kjaergaard; Jens Dam Jensen; Kent Lodberg Christensen; Charlotte Strandhave; Ida Noerager Tietze; Marija Kristina Novosel; Bo Martin Bibby; Bente Jespersen
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

4.  Calcium channel blockers for people with chronic kidney disease requiring dialysis.

Authors:  George A Mugendi; Florence M Mutua; Patrizia Natale; Tonya M Esterhuizen; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2020-10-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.